Background and Aim: The GALAD score, a mathematical model incorporating gender, age, alpha-fetoprotein (AFP), the lens culinaris agglutinin-reactive fraction of AFP (AFP-L3), and des-gamma-carboxy prothrombin (DCP), has been developed to assess the presence of hepatocellular carcinoma (HCC) in patients with chronic liver disease. This study aimed to evaluate the efficacy of the GALAD score in predicting and assessing the prognosis of hepatitis C–related HCC in patients who had received prior direct-acting antiviral (DAA) treatment. Materials and Methods: This case-control study included patients with HCV-related liver cirrhosis treated with DAAs, with or without HCC, recruited from the HCC clinic at Kasr Al-Ainy Hospital, Cairo University, and followed until death or the end of the study. Data included clinical and laboratory parameters, DCP, AFP, and AFP-L3 levels, imaging findings, treatment response, and survival. Logistic regression was used to identify independent predictors of HCC, mortality, and recurrence. Results: Eighty-eight patients with HCV-related HCC following DAA treatment and 88 patients without HCC were recruited, with no significant differences in gender or age between the groups. Participants with HCC had a higher mean GALAD score (4.32±2.47 vs. 1.32±1.46, p